Dimerix Limited announced it has licensed its proprietary Receptor-HIT assay to Excellerate Bioscience. Under the non-exclusive Agreement, Excellerate will offer Receptor-HIT to leading pharmaceutical and biotechnology companies, as well as academic institutes, as part of its world-class expertise in assay technology on which Dimerix will receive an undisclosed royalty on gross revenues of the service fee. Both companies will market the Receptor-HIT offering and Excellerate Bioscience will run the assay service from its new facility in BioCity, Nottingham UK. The licensing of Receptor-HIT to Excellerate Bioscience further commercialises the technology on which Dimerix was originally founded, whilst Dimerix continues to concentrate on its core business of developing innovative new therapies in areas with unmet medical needs.